SAFETY DATA SHEET

Gentamicin / Betamethasone Formulation

SECTION 1. IDENTIFICATION

Product name: Gentamicin / Betamethasone Formulation

Manufacturer or supplier’s details
Company name of supplier: Merck & Co., Inc
Address: 126 E. Lincoln Avenue, Rahway, New Jersey U.S.A. 07065
Telephone: 908-740-4000
Emergency telephone: 1-908-423-6000
E-mail address: EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use: Veterinary product
Restrictions on use: Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Reproductive toxicity: Category 1A
Specific target organ toxicity - repeated exposure: Category 1 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland)

GHS label elements
Hazard pictograms: 

Signal Word: Danger
Hazard Statements: H360D May damage the unborn child.
H372 Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Precautionary Statements: Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe mist or vapors.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves, protective clothing, eye protection and face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical attention.
SAFETY DATA SHEET

Gentamicin / Betamethasone Formulation

Storage:
P405 Store locked up.

Disposal:
P501 Dispose of contents and container to an approved waste disposal plant.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture: Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyethylene glycol stearate</td>
<td>9004-99-3</td>
<td>5</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>0.49</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>378-44-9</td>
<td>0.1</td>
</tr>
</tbody>
</table>

SECTION 4. FIRST AID MEASURES

General advice: In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled: If inhaled, remove to fresh air. Get medical attention.

In case of skin contact: In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

If swallowed: If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed: May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Unsuitable extinguishing media: None known.
Specific hazards during fire fighting: Exposure to combustion products may be a hazard to health.
Hazardous combustion products: Carbon oxides

Specific extinguishing methods:
- Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
- Use water spray to cool unopened containers.
- Remove undamaged containers from fire area if it is safe to do so.
- Evacuate area.

Special protective equipment for fire-fighters:
- In the event of fire, wear self-contained breathing apparatus.
- Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g., by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
- Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling:
- Do not get on skin or clothing.
- Do not breathe mist or vapors.
- Do not swallow.
Avoid contact with eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage: Keep in properly labeled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Materials to avoid: Do not store with the following product types:
- Strong oxidizing agents
- Self-reactive substances and mixtures
- Organic peroxides
- Explosives
- Gases

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyethylene glycol stearate</td>
<td>9004-99-3</td>
<td>TWA (Inhalable particulate matter)</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable particulate matter)</td>
<td>3 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Betamethasone</td>
<td>378-44-9</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information:
- Gentamicin: OTO
- Betamethasone: Skin Wipe limit: 10 µg/100 cm² | Internal |

Engineering measures: All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Essentially no open handling permitted. Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment
Respiratory protection: General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where
concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Hand protection

Material

Chemical-resistant gloves

Remarks

Consider double gloving.

Eye protection

Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures

If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

liquid

Color

No data available

Odor

No data available

Odor Threshold

No data available

pH

No data available

Melting point/freezing point

No data available

Initial boiling point and boiling range

No data available
Flash point : No data available
Evaporation rate : No data available
Flammability (solid, gas) : Not applicable
Flammability (liquids) : No data available
Upper explosion limit / Upper flammability limit : No data available
Lower explosion limit / Lower flammability limit : No data available
Vapor pressure : No data available
Relative vapor density : No data available
Relative density : No data available
Density : No data available
Solubility(ies)
   Water solubility : No data available
Partition coefficient: n-octanol/water
   Autoignition temperature : No data available
Decomposition temperature : No data available
Viscosity
   Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : Can react with strong oxidizing agents.
Conditions to avoid : None known.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.
SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute inhalation toxicity : Acute toxicity estimate: > 200 mg/l
  Exposure time: 4 h
  Test atmosphere: dust/mist
  Method: Calculation method

Components:

Polyethylene glycol stearate:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Gentamicin:
Acute oral toxicity : LD50 (Rat): 8,000 - 10,000 mg/kg
                    LD50 (Mouse): 10,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0.2 mg/l
                           Exposure time: 4 h
                           Test atmosphere: dust/mist
                           Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): 67 - 96 mg/kg
                              Application Route: Intravenous
                              LD50 (Rat): 371 - 384 mg/kg
                              Application Route: Intramuscular
                              LDLo (Monkey): 30 mg/kg
                              Application Route: Intravenous

Betamethasone:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
                    LD50 (Mouse): > 4,500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0.4 mg/l
                          Exposure time: 4 h

Skin corrosion/irritation
Not classified based on available information.
Components:

Polyethylene glycol stearate:
Species: Rabbit
Method: Draize Test
Result: No skin irritation

Gentamicin:
Species: Rabbit
Result: Mild skin irritation

Betamethasone:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Polyethylene glycol stearate:
Species: Rabbit
Result: No eye irritation
Method: Draize Test

Gentamicin:
Species: Rabbit
Result: Mild eye irritation

Betamethasone:
Species: Rabbit
Result: No eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.

Components:

Polyethylene glycol stearate:
Test Type: Open epicutaneous test
Routes of exposure: Skin contact
Species: Guinea pig
Result: negative

Gentamicin:
Remarks: No data available
Betamethasone:
Routes of exposure : Dermal
Species : Guinea pig
Result : Weak sensitizer

Germ cell mutagenicity
Not classified based on available information.

Components:

Polyethylene glycol stearate:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Gentamicin:
Genotoxicity in vitro : Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

Betamethasone:
Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: positive

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Oral
Result: equivocal

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity
Not classified based on available information.
Components:

Gentamicin:
Carcinogenicity - Assessment
IARC: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.

NTP: No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
May damage the unborn child.

Components:

Gentamicin:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Fertility: NOAEL: 20 mg/kg body weight
Result: No significant adverse effects were reported

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rabbit
Developmental Toxicity: NOAEL: 3.6 mg/kg body weight
Result: No embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 75 mg/kg body weight
Result: Embryo-fetal toxicity.

Test Type: Embryo-fetal development
Species: Mouse
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 10 mg/kg body weight
Result: Fetal mortality., No malformations were observed.

Test Type: Embryo-fetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 50 mg/kg body weight
Result: Fetal mortality., No malformations were observed.

Reproductive toxicity - Assessment: Positive evidence of adverse effects on development from human epidemiological studies.

Betamethasone:
Effects on fetal development: Species: Rabbit
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 0.05 mg/kg body weight
Result: Fetotoxicity., Malformations were observed.

Species: Rat
Application Route: Subcutaneous
Developmental Toxicity: LOAEL: 0.42 mg/kg body weight
Result: Malformations were observed.

Species: Mouse
Application Route: Intramuscular
Developmental Toxicity: LOAEL: 1 mg/kg body weight
Result: Malformations were observed.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

STOT-single exposure
Not classified based on available information.

STOT-repeated exposure
Causes damage to organs (Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland) through prolonged or repeated exposure.

Components:

Gentamicin:
Target Organs : Kidney, inner ear
Assessment : Causes damage to organs through prolonged or repeated exposure.

Betamethasone:
Target Organs : Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Gentamicin:
Species : Dog
LOAEL : 3 mg/kg
Application Route : Intramuscular
Exposure time : 12 Months
Target Organs : Kidney
Symptoms : Vomiting, Salivation

Species : Monkey
LOAEL : 50 mg/kg
Application Route : Subcutaneous
Exposure time : 3 Weeks
Target Organs : Kidney, inner ear
Species : Monkey  
**LOAEL** : 6 mg/kg  
Application Route : Intramuscular  
Exposure time : 3 Weeks  
Target Organs : Blood, Kidney, inner ear, Liver

Species : Rat  
**NOAEL** : 5 mg/kg  
**LOAEL** : 10 mg/kg  
Application Route : Intramuscular  
Exposure time : 52 Weeks  
Target Organs : Kidney, Blood

Species : Rat  
**NOAEL** : 12.5 mg/kg  
**LOAEL** : 50 mg/kg  
Application Route : Intramuscular  
Exposure time : 13 Weeks  
Target Organs : Kidney

**Betamethasone:**
Species : Rabbit  
**LOAEL** : 0.05 %  
Application Route : Skin contact  
Exposure time : 10 - 30 d  
Target Organs : Pituitary gland, Immune system, muscle

Species : Rat  
**LOAEL** : 0.05 %  
Application Route : Skin contact  
Exposure time : 8 Weeks  
Target Organs : thymus gland

Species : Mouse  
**LOAEL** : 0.1 %  
Application Route : Skin contact  
Exposure time : 8 Weeks  
Target Organs : thymus gland

Species : Dog  
**LOAEL** : 0.05 mg/kg  
Application Route : Oral  
Exposure time : 28 d  
Target Organs : Blood, thymus gland, Adrenal gland

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

**Components:**

**Gentamicin:**
Ingestion : Target Organs: Kidney
SAFETY DATA SHEET

Gentamicin / Betamethasone Formulation

Target Organs: inner ear
Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

Betamethasone:
Inhalation
Skin contact

<table>
<thead>
<tr>
<th>Ecotoxicity</th>
<th>Components:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Polyethylene glycol stearate:</td>
<td></td>
</tr>
<tr>
<td>Toxicity to fish</td>
<td>LC50 (Leuciscus idus (Golden orfe)): &gt; 10,000 mg/l</td>
</tr>
<tr>
<td>Exposure time: 96 h</td>
<td></td>
</tr>
<tr>
<td>Method: DIN 38412</td>
<td></td>
</tr>
<tr>
<td>Toxicity to microorganisms</td>
<td>EC10 (Bacteria): &gt; 10,000 mg/l</td>
</tr>
<tr>
<td>Exposure time: 16 h</td>
<td></td>
</tr>
</tbody>
</table>

Gentamicin:
Toxicity to daphnia and other aquatic invertebrates:
EC50 (Daphnia magna (Water flea)): 86 mg/l |
| Exposure time: 48 h |
| Method: OECD Test Guideline 202 |
| LC50 (Americamysis): 30 mg/l |
| Exposure time: 96 h |
| Method: US-EPA OPPTS 850.1035 |

Toxicity to algae/aquatic plants:
EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l |
| Exposure time: 72 h |
| Method: OECD Test Guideline 201 |
| NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l |
| Exposure time: 72 h |
| Method: OECD Test Guideline 201 |
| EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l |
| Exposure time: 72 h |
| Method: OECD Test Guideline 201 |
| NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l |
| Exposure time: 72 h |
| Method: OECD Test Guideline 201 |

Toxicity to microorganisms:
EC50: 288.7 mg/l |
| Exposure time: 3 h |
| Test Type: Respiration inhibition |
| Method: OECD Test Guideline 209 |
Toxicity to daphnia and other aquatic invertebrates: EC50 (Americamysis): > 50 mg/l
Exposure time: 96 h

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility.

Toxicity to fish (Chronic toxicity): NOEC (Pimephales promelas (fathead minnow)): 0.052 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

NOEC (Oryzias latipes (Japanese medaka)): 0.07 µg/l
Exposure time: 219 d
Method: OECD Test Guideline 229

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity): NOEC (Daphnia magna (Water flea)): 8 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Persistence and degradability

Components:

Polyethylene glycol stearate:
Biodegradability: Result: Readily biodegradable.
Biodegradation: > 70 %
Exposure time: 10 d
Method: OECD Test Guideline 302B

Gentamicin:
Biodegradability: Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Gentamicin:
Partition coefficient: n-octanol/water: log Pow: < -2

Betamethasone:
Partition coefficient: n-octanol/water: log Pow: 2.11
Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Do not dispose of waste into sewer.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Gentamicin, Benzalkonium chloride)
Class: 9
Packing group: III
Labels: 9

IATA-DGR
UN/ID No.: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s.
(Gentamicin, Benzalkonium chloride)
Class: 9
Packing group: III
Labels: Miscellaneous
Packing instruction (cargo aircraft): 964
Packing instruction (passenger aircraft): 964
Environmentally hazardous: yes

IMDG-Code
UN number: UN 3082
Proper shipping name: ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Gentamicin, Benzalkonium chloride)
Class: 9
Packing group: III
Labels: 9
EmS Code: F-A, S-F
Marine pollutant: yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation
SAFETY DATA SHEET

Gentamicin / Betamethasone Formulation

Version 6.9 Revision Date: 04/04/2023 SDS Number: 434598-00021 Date of last issue: 10/01/2022 Date of first issue: 01/06/2016

49 CFR
UN/ID/NA number: UN 3082
Proper shipping name: Environmentally hazardous substance, liquid, n.o.s. (Gentamicin, Benzalkonium chloride)
Class: 9
Packing group: III
Labels: CLASS 9
ERG Code: 171
Marine pollutant: yes (Gentamicin, Benzalkonium chloride)
Remarks: Above applies only to containers over 119 gallons or 450 liters.
Shipment by ground under DOT is non-regulated; however it may be shipped per the applicable hazard classification to facilitate multi-modal transport involving ICAO (IATA) or IMO.

Special precautions for user
The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
This material does not contain any components with a CERCLA RQ.

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards: Reproductive toxicity
Specific target organ toxicity (single or repeated exposure)

SARA 313: This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations
Pennsylvania Right To Know
Water 7732-18-5
Polyethylene glycol stearate 9004-99-3
Polyethylene glycol castor oil 61791-12-6

California Prop. 65
WARNING: This product can expose you to chemicals including Gentamicin, which is/are known to the State of California to cause birth defects or other reproductive harm. For more information go to www.P65Warnings.ca.gov.

The ingredients of this product are reported in the following inventories:
AICS: not determined
SECTION 16. OTHER INFORMATION

Further information

NFPA 704:  

HMIS® IV:

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "**" represents a chronic hazard, while the "*" represents the absence of a chronic hazard.

Full text of other abbreviations
ACGIH: USA. ACGIH Threshold Limit Values (TLV)
ACGIH / TWA: 8-hour, time-weighted average

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECX - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of
SAFETY DATA SHEET

Gentamicin / Betamethasone Formulation

Revision Date: 04/04/2023
SDS Number: 434598-00021
Date of last issue: 10/01/2022
Date of first issue: 01/06/2016

Sources of key data used to compile the Material Safety Data Sheet:

Revision Date: 04/04/2023

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

US / Z8